Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Profound Medical Corp

Healthcare CA PRN

9.27CAD
-0.05(0.54%)

Last update at 2026-06-12T20:00:00Z

Day Range

9.239.34
LowHigh

52 Week Range

5.2312.40
LowHigh

Fundamentals

  • Previous Close 9.32
  • Market Cap338.98M
  • Volume911
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-40.69400M
  • Revenue TTM16.10M
  • Revenue Per Share TTM0.53
  • Gross Profit TTM 11.39M
  • Diluted EPS TTM-1.94

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.13046M -27.81800M -28.69700M -28.38200M -30.59400M
Minority interest - - - - -
Net income -59.48257M -27.81600M -28.56900M -28.66900M -30.69900M
Selling general administrative 32.05M 23.13M 9.17M 9.46M 10.31M
Selling and marketing expenses - - 9.45M 8.47M 7.65M
Gross profit 15.92M 7.04M 4.38M 3.02M 2.95M
Reconciled depreciation 0.56M 0.94M 1.15M 1.60M 1.88M
Ebit -57.64374M -33.06200M -27.92700M -29.60200M -30.29100M
Ebitda -56.86126M -32.12600M -26.99800M -25.47400M -28.41200M
Depreciation and amortization 0.78M 0.94M 0.93M 4.13M 1.88M
Non operating income net other - - - - -
Operating income -57.64374M -33.06200M -28.61600M -29.60200M -30.29100M
Other operating expenses 80.14M 43.74M 35.81M 36.28M 37.16M
Interest expense - - 0.77M 0.17M 0.30M
Tax provision 0.25M -0.00200M -0.12800M 0.29M 0.10M
Interest income - 5.24M 1.64M 3.45M 0.14M
Net interest income 1.07M 1.44M 0.73M 0.92M -0.31000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.35M -0.00200M -0.12800M 0.29M 0.10M
Total revenue 22.49M 10.68M 7.20M 6.68M 6.87M
Total operating expenses 73.56M 40.10M 33.00M 32.62M 33.24M
Cost of revenue 6.57M 3.64M 2.82M 3.66M 3.92M
Total other income expense net -1.48672M 5.24M -0.08100M 1.22M -0.30300M
Discontinued operations - - - - -
Net income from continuing ops -42.57000M -27.81600M -28.56900M -28.66900M -30.69900M
Net income applicable to common shares - -27.81600M -28.32300M -28.66900M -30.69900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 193.10M 70.23M 43.91M 64.42M 86.78M
Intangible assets 0.19M 0.26M 0.49M 0.68M 1.44M
Earning assets - - - - -
Other current assets 3.94M - 1.41M 1.22M 1.15M
Total liab 102.04M 9.81M 12.73M 12.42M 6.16M
Total stockholder equity 91.06M 60.42M 31.18M 52.00M 80.62M
Deferred long term liab - - - - -
Other current liab 5.07M 0.33M - 0.92M 0.25M
Common stock 443.90M - 217.39M 205.82M 219.58M
Capital stock 323.84M 281.55M 217.39M 205.82M 219.58M
Retained earnings -394.41960M -245.17000M -217.93100M -189.36200M -160.69300M
Other liab - - - 0.76M 0.88M
Good will - - - 0.00000M 2.69M
Other assets - - - - 3.62M
Cash 81.87M 54.91M 26.21M 46.52M 67.15M
Cash and equivalents - - - - -
Total current liabilities 8.33M 6.57M 6.37M 4.18M 4.16M
Current deferred revenue 0.61M - 0.72M 0.47M 0.48M
Net debt -75.40633M - -18.27200M -38.28700M -65.77500M
Short term debt 0.50M - 2.36M 0.76M 0.25M
Short long term debt - 1.74M 2.10M 0.52M -
Short long term debt total 6.46M - 7.94M 8.23M 1.38M
Other stockholder equity 34.69M - 19.69M 18.70M 16.99M
Property plant equipment - - - 1.72M 1.90M
Total current assets 104.30M 69.06M 41.90M 62.02M 77.12M
Long term investments - - - - -
Net tangible assets - - - 51.32M 76.49M
Short term investments - - - - -
Net receivables 7.20M 6.58M 7.29M 6.34M 1.41M
Long term debt 4.50M 2.92M 5.00M 6.65M -
Inventory 11.29M 5.80M 6.99M 7.94M 7.41M
Accounts payable 2.14M 1.32M 3.28M 2.03M 3.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 6.89M - 12.03M 16.84M 4.75M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 3.62M
Deferred long term asset charges - - - - -
Non current assets total 88.80M 1.17M 2.02M 2.40M 9.65M
Capital lease obligations 0.21M 0.46M 0.84M 1.06M 1.38M
Long term debt total - - - 7.47M 1.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - 0.00000M -0.59300M
Change to liabilities - - - -0.56600M -0.35600M
Total cashflows from investing activities -0.33814M - - 0.00000M -0.59300M
Net borrowings -0.29000M -2.56000M -0.91200M 6.92M -0.38600M
Total cash from financing activities 57.48M 54.70M 1.46M 7.03M 5.95M
Change to operating activities - - - -2.08600M -0.01300M
Net income -59.48257M -27.81600M -28.32300M -28.66900M -30.69900M
Change in cash 2.89M 28.70M -20.30400M -20.63500M -16.76100M
Begin period cash flow 78.97M 26.21M 46.52M 67.15M 83.91M
End period cash flow 81.87M 54.91M 26.21M 46.52M 67.15M
Total cash from operating activities -53.38620M -23.45300M -22.60900M -25.80000M -22.36000M
Issuance of capital stock 42.44M 62.11M 0.00000M - 0.00000M
Depreciation 0.78M 0.94M 1.15M 1.60M 1.88M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -3.94315M 0.66M 0.35M -1.86400M -2.49100M
Change to account receivables -0.24033M 0.19M -1.41300M -1.42400M 2.00M
Sale purchase of stock - 62.15M 2.67M 0.26M 6.43M
Other cashflows from financing activities - -4.85000M 2.67M 7.39M 6.33M
Change to netincome - - - 6.89M 7.34M
Capital expenditures 0.25M 0.00000M 0.00000M 0.00000M 0.59M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.39356M 0.59M 0.54M -5.62900M -0.87700M
Stock based compensation 5.49M 2.58M 3.42M 4.24M 7.21M
Other non cash items 7.71M 0.26M 0.38M 2.66M 0.13M
Free cash flow -53.63213M -23.45300M -22.29700M -25.80000M -22.95300M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRN
Profound Medical Corp		 -0.05 0.54% 9.27 - - 21.06 3.72 11.94 -7.9326

Reports Covered

Stock Research & News

View All

Profile

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical Corp

2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5

Key Executives

Name Title Year Born
Dr. Arun Swarup Menawat MBA, Ph.D. Chairman & CEO 1955
Mr. Rashed Dewan Chief Financial Officer 1968
Dr. Mathieu Burtnyk Sr. VP of Product Leader TULSA-PRO 1982
Mr. Stephen Kilmer Investor Relations NA
Mr. Hartmut Warnken Chief Commercial Officer of OUS NA
Mr. Jacques F. Cornet Sr. VP & Product Leader Sonalleve 1956
Mr. Michael Mydra VP & Head of Global Market Access NA
Mr. Abbey Goodman Chief Commercial Officer of US NA
Mr. Matthew Sobczyk C.A., CPA Assistant Corp. Controller NA
Mr. Levant Tinaz Software Developer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.